BCTX Key Statistics, Chart & Performance
The current stock price of BCTX is 7.64 USD. In the past month the price decreased by -25.9%. In the past year, price decreased by -98.65%.
BCTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.28 | 388.89B | ||
| AMGN | AMGEN INC | 14.89 | 175.30B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.53 | 116.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 727.27 | 49.00B | ||
| INSM | INSMED INC | N/A | 35.77B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 11.09 | 27.23B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.65B | ||
| INCY | INCYTE CORP | 16.56 | 20.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.28 | 20.77B |
Related stock screener links
About BCTX
Company Profile
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
BRIACELL THERAPEUTICS CORP
Suite 300 - Bellevue Centre, 235 -15th Street
West Vancouver BRITISH COLUMBIA V7T 2X1 CA
CEO: William V. Williams
Employees: 20
Phone: 16049211810
BRIACELL THERAPEUTICS CORP / BCTX FAQ
What does BRIACELL THERAPEUTICS CORP do?
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Can you provide the latest stock price for BRIACELL THERAPEUTICS CORP?
The current stock price of BCTX is 7.64 USD. The price increased by 5.38% in the last trading session.
Does BCTX stock pay dividends?
BCTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCTX stock?
BCTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does BRIACELL THERAPEUTICS CORP belong to?
BRIACELL THERAPEUTICS CORP (BCTX) operates in the Health Care sector and the Biotechnology industry.
What is BRIACELL THERAPEUTICS CORP worth?
BRIACELL THERAPEUTICS CORP (BCTX) has a market capitalization of 14.36M USD. This makes BCTX a Nano Cap stock.
When does BRIACELL THERAPEUTICS CORP (BCTX) report earnings?
BRIACELL THERAPEUTICS CORP (BCTX) will report earnings on 2026-03-10.
BCTX Technical Analysis
BCTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BCTX. While BCTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
BCTX Financial Highlights
Over the last trailing twelve months BCTX reported a non-GAAP Earnings per Share(EPS) of -128.19. The EPS decreased by -184.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -219.56% | ||
| ROE | -287.71% | ||
| Debt/Equity | 0 |